Wuxi Bio to Sell Vaccine Facility to Merck

WuXi Biologics to Sell Irish Vaccine Facility to Merck for $500 Million
WuXi Biologics’ move to sell the facility could strengthen the company’s cash flow and margins as it navigates global uncertainties.
In €500M deal, Merck buys Ireland vaccines plant from CDMO WuXi Biologics
In Ireland, WuXi Biologics has sold a new vaccines plant to Merck & Co. for €500 million ($521 million). The New Jersey company was a natural buyer of the facility as it was the lone client WuXi Biologics served at the site in Dundalk, executing a 20-year contract to produce vaccines worth $150 million annually.
WuXi Bio to Sell Vaccine Facility to Merck for $500 Million
WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese company seeks to enhance its margins while continuing to navigate geopolitical tensions.
China's WuXi Biologics to sell Irish vaccine facility to Merck as US curbs loom
China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co for about $500 million, ahead of potential U.S. legislation that would restrict business for Chinese biotech companies.
China’s WuXi Biologics to sell vaccine facility to Merck for US$500 million
WUXI Biologics Cayman will sell a vaccine facility in Ireland to Merck for about US$500 million as the Chinese company seeks to enhance its margins while continuing to navigate geopolitical tensions.
Merck to buy vaccine plant from WuXi Biologics: report
WuXi Biologics (OTCPK:WXIBF) is reportedly selling its vaccine facility in Ireland to Merck (NYSE:MRK) as part of a previously announced plan to divest some of its assets. The China-based contract research,
WuXi AppTec deal eases pressure from Congress on Penn and CHOP biotech
WuXi AppTec, the Shanghai-based biotech giant, has sold its South Philly-based WuXi Advanced Therapies contract manufacturing ...
Rapafusyn Pharmaceuticals to Showcase Its Molecular Glue Drug Discovery Platform at WuXi Global Forum
BALTIMORE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Rapafusyn Pharmaceuticals, a pioneer in non-degrading molecular glue therapeutics, announced today that it will host an executive roundtable at the WuXi ...
FierceBiotech1d
Candid's T-cell engager shopping spree rolls on with WuXi Biologics pact worth up to $925M
Candid Therapeutics is continuing its mission to flesh out a pipeline of T-cell engagers in record time, signing a ...
GEN17h
Candid Therapeutics Enters into Agreement with WuXi Biologics on Trispecific T-Cell Engager
WuXi upgraded its WuXiBody platform in bispecific antibody discovery to address the growing global demand for these complex ...
Drug giant MSD buys Wuxi’s Irish vaccines plant in €500m deal
US pharmaceutical group adds eighth Irish manufacturing site to its network as it promises to deliver 1,000 jobs this year ...
Wuxi Biologics upgraded to Overweight from Neutral at JPMorgan
JPMorgan upgraded Wuxi Biologics (WXXWY) to Overweight from Neutral with a price target of HK$20, up from HK$13, citing expected order growth ...
ENDPOINTS NEWS1d
Ken Song's Can­did li­cens­es a T cell en­gager from WuXi Bio
Candid Therapeutics commits $925M for WuXi Biologics' T cell engager rights. CEO Ken Song aims for human trials in 2026, ...
Join LOBO EV’s Exclusive Live Investor Webinar and Q&A Session on January 8
LOBO EV Technologies Ltd. (Nasdaq: LOBO) (“LOBO” or the “Company”), an innovative e-bicycle, e-moped, e-tricycle, and electric off-highway four-wheeled shuttle designer, developer, manufacturer and ...